Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Convergence Pharmaceuticals has commenced the multiple ascending dose Phase I study of CNV2197944, a calcium channel blocker used to treat chronic pain.
Subscribe to our email newsletter
The randomised, placebo controlled Phase I study is intended to assess the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944.
Recently, ascending dose Phase I study with orally administered CNV2197944 was recently completed, which demonstrated that the drug candidate was well tolerated and showed an ideal pharmacokinetic profile for the target indication of chronic pain.
Convergence Pharmaceuticals CEO Clive Dix said CNV2197944 would be a safe and effective long term treatment for chronic pain as evident from the data.
The company is likely to conclude the study in 2Q 2012.